Cataract Surgery and BPH Management

Condition Overview

• BPH is a non-cancerous enlargement of the prostate gland, causing lower urinary tract symptoms (LUTS) through both static and dynamic components, with symptoms including weak stream, hesitancy, frequency, urgency, and nocturia 1

Preoperative Considerations

• The American Urological Association recommends alerting your ophthalmologist about tamsulosin use before any eye surgery, as it may cause complications, particularly intraoperative floppy iris syndrome 2
• Patients with planned cataract surgery should be informed about the risk of intraoperative floppy iris syndrome, as reported in The Journal of Urology 2

Medication Management

• Alpha-blocking medications include alpha-1 selective blockers, non-selective alpha-1 blockers, and combined alpha/beta blockers, as recommended by the American College of Cardiology 3
• Doxazosin, terazosin, and alfuzosin are non-selective alpha blockers, while tamsulosin and silodosin are selective alpha blockers, with varying rates of ejaculatory dysfunction and orthostatic hypotension, as noted by the European Association of Urology and the American Urological Association 4, 5, 2
• The following table summarizes the characteristics of different alpha blockers:

4, 5

• Tamsulosin can be started at 0.4mg daily and increased to 0.8mg if needed, as advised by the American Urological Association 2, 4, 5
• Doxazosin can be dosed at 1-16mg daily, and terazosin can be dosed at 1-20mg daily or divided, as recommended by the American College of Cardiology 3

Combination Therapy

• The European Association of Urology supports the use of alpha-blocker + 5-alpha reductase inhibitor for enlarged prostates, as this combination has demonstrated efficacy and safety 5
• The European Association of Urology also recommends alpha-blocker + antimuscarinic for storage symptoms, and alpha-blocker + beta-3 agonist for overactive bladder symptoms, as these combinations have shown to be effective 5

Follow-up and Monitoring

• The American Urological Association recommends returning for evaluation within 2-4 weeks after starting tamsulosin, and regular annual follow-ups to assess ongoing symptom control 2, 1
• Patients should be scheduled for follow-up within 2-4 weeks to assess for adverse effects, and ophthalmologists should be informed about alpha-blocker use due to the risk of intraoperative floppy iris syndrome, as suggested by the European Association of Urology 6, 5
• The American Heart Association recommends achieving blood pressure control within 3 months of initiating terazosin therapy, with regular blood pressure checks during the first 2-4 weeks of treatment 7
• The European Society of Cardiology suggests monitoring both supine and standing blood pressure to assess for orthostatic hypotension in patients taking terazosin 8

Expected Improvements and Long-term Expectations

• Symptom improvement from tamsulosin typically begins within 2-4 weeks, with benefits including reduced urinary frequency, improved flow rate, and decreased nighttime urination 2
• Tamsulosin helps manage symptoms but does not shrink the prostate, with long-term effectiveness maintained for over a year, although some patients may eventually need combination therapy or surgical intervention if symptoms progress 9

Lifestyle Modifications

• Reducing fluid intake before bedtime can help minimize nighttime urination, with a recommended urine output of about 1 liter/24 hours 1

Special Considerations

• Patients should be counseled about the potential for ejaculatory dysfunction before starting tamsulosin therapy, and alternative alpha blockers or dose modification strategies can be considered for men who are particularly concerned about this side effect 4, 5
• Hypertension should be managed with agents other than alpha-blockers, such as low-dose thiazide diuretics, long-acting calcium channel blockers, ACE inhibitors, or ARBs, as suggested by the American College of Cardiology 6
• Consider non-alpha blocker alternatives for managing related conditions, such as SSRIs, cognitive behavioral therapy for insomnia (CBT-I), and other psychiatric medications that don't have alpha-blocking properties 5